Comparison · NCT03775109-sae
Canakinumab vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Canakinumab vs Placebo: serious adverse events. Trial comparisons, record NCT03775109-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03775109-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.357 | 0.207 | 0.542 | wilson | |
| Risk in group 2 | 0.37 | 0.215 | 0.558 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0132 | -0.253 | 0.228 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.964 | 0.479 | 1.94 | log | |
| Odds ratio, group 1 over group 2 | 0.944 | 0.315 | 2.83 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Canakinumab than on Placebo | 75.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Canakinumab | A single dose of 3 mg/kg canakinumab administered intravenously at baseline. Canakinumab made up by dilution in 100ml 5% dextrose solution.~Patients with AST \> 2 x ULN on day 28 receive a second dose of 3mg/kg canakinumab administered the same way. | 10 | 28 | EG000 |
| Group 2 | Placebo | A single injection of 100ml 5% Dextrose solution at baseline.~Patients with AST \> 2 x ULN on day 28 receive a second injection of the same solution. | 10 | 27 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 90 days
Source ClinicalTrials.gov
Trial
- Title
- IL-1 Signal Inhibition in Alcoholic Hepatitis
- NCT number
- NCT03775109
- Phases
- PHASE2
- Conditions
- Alcoholic Hepatitis
- Interventions
- Canakinumab 150mg/ml solution for injection, Placebo
- Lead sponsor
- Imperial College London
- Results first posted
- 2025-03-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03775109?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03775109-sae